Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis

Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis

<strong>Objective</strong> Magnetic resonance imaging (MRI) was used in a Phase IIb study (NCT01185353) of baricitinib in patients with RA to support dose selection for the Phase III program. <strong>Methods</strong> 301 patients with active RA on stable methotrexate were ra...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Peterfy, C, Dicarlo, J, Emery, P, Genovese, MC, Keystone, EC, Taylor, PC, Schlichting, DE, Beattie, SD, Luchi, M, Macias, W
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	Journal of Rheumatology 2019

Ижил төстэй зүйлс

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
-н: Peterfy, C, зэрэг
Хэвлэсэн: (2012)

Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis
-н: Keystone, EC, зэрэг
Хэвлэсэн: (2017)

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
-н: Genovese, M, зэрэг
Хэвлэсэн: (2012)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
-н: Keystone, E, зэрэг
Хэвлэсэн: (2015)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
-н: Taylor, P, зэрэг
Хэвлэсэн: (2013)

Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase 2b study in patients with active rheumatoid arthritis
-н: Kremer, J, зэрэг
Хэвлэсэн: (2017)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
-н: Ronald van Vollenhoven, зэрэг
Хэвлэсэн: (2018-10-01)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
-н: Paul Emery, зэрэг
Хэвлэсэн: (2020-07-01)

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
-н: Emery, P, зэрэг
Хэвлэсэн: (2017)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: A matching-adjusted indirect comparison
-н: Fautrel, B, зэрэг
Хэвлэсэн: (2020)

Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
-н: Abhishek Zanwar, зэрэг
Хэвлэсэн: (2017-01-01)

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
-н: Tanaka, Y, зэрэг
Хэвлэсэн: (2018)

Predictors of radiological progression of rheumatoid arthritis while receiving conventional synthetic disease-modifying antirheumatic drugs
-н: O. B. Iaremenko, зэрэг
Хэвлэсэн: (2024-12-01)

Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.
-н: Emery, P, зэрэг
Хэвлэсэн: (1994)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
-н: P Emery, зэрэг
Хэвлэсэн: (2020-02-01)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
-н: Susan Siyu Wang, зэрэг
Хэвлэсэн: (2023-07-01)

Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis
-н: Yoshifumi Tada, зэрэг
Хэвлэсэн: (2021-01-01)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
-н: Taylor, PC, зэрэг
Хэвлэсэн: (2023)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2016)

The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
-н: Gregory Fleury, зэрэг
Хэвлэсэн: (2017-12-01)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
-н: Weinblatt, M, зэрэг
Хэвлэсэн: (2017)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Baricitinib exposure during pregnancy in rheumatoid arthritis
-н: Giulia Costanzo, зэрэг
Хэвлэсэн: (2020-01-01)

Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
-н: Richard Conway, зэрэг
Хэвлэсэн: (2021-01-01)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
-н: Strand, V, зэрэг
Хэвлэсэн: (2021)

Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
-н: Suad Mohammed, зэрэг
Хэвлэсэн: (2019-01-01)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
-н: Shuzo Sato, зэрэг
Хэвлэсэн: (2021-08-01)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
-н: Smolen, J, зэрэг
Хэвлэсэн: (2017)

Pain reduction in rheumatoid arthritis patients who use opioids: a post hoc analysis of phase 3 trials of baricitinib
-н: Pope, JE, зэрэг
Хэвлэсэн: (2021)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
-н: Gerd Burmester, зэрэг
Хэвлэсэн: (2020-02-01)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2018)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
-н: Gulsen Ozen, зэрэг
Хэвлэсэн: (2019-06-01)

Cutaneous eruption after commencing baricitinib for rheumatoid arthritis
-н: Rosemary Akinbisehin, зэрэг
Хэвлэсэн: (2024-06-01)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
-н: Emery, P, зэрэг
Хэвлэсэн: (2019)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
-н: Judge, AD, зэрэг
Хэвлэсэн: (2017)